AstraZeneca completes divestment of Caprelsa cancer drug
AstraZeneca has finalised the divestment of cancer drug Caprelsa to Genzyme.
AstraZeneca
9,915.00p
17:15 18/11/24
-0.63%
-63.00p
FTSE 100
8,109.32
16:35 18/11/24
n/a
n/a
FTSE 350
4,473.50
17:09 18/11/24
n/a
n/a
FTSE All-Share
4,431.13
16:49 18/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,204.40
17:09 18/11/24
-0.28%
-53.32
The FTSE 100 company confirmed the news on Wednesday.
Genzyme paid AstraZeneca $165m to acquire the global rights to sell and develop the drug, and will make further milestone payments of up to $135m.
It said the divestment reinforces AstraZeneca's strategic focus on its three main therapy areas, and the transaction doesn’t impact the company’s financial guidance for the year.